Comparison of Gabapentin With Doxepin in the Management of Uremic Pruritus

Status Completed

Clinical Trial Summary

This is a single blind randomized trial to compare efficacy and side effects of Gabapentin with Doxepin. Hemodialysis patients with uremic pruritus at one dialysis center of Saint George Hospital University Medical Centre were included in this study. Patients were divided into 2 groups to receive either 10 mg Doxepin daily or Gabapentin at a dose of 100mg after each hemodialysis session (increased as tolerated) for 4 weeks, after which patients were treated reversley. Pruritus severity and its effect on quality of life will be assessed by using visual analog scale (VAS), 5-D pruritus scale and dermatology life quality index (DLQI). Include patients will have to fill these forms at baseline and at end of week1, week2 and week4

Clinical Trial Description

Pruritus is one of the frustrating skin manifestations of advanced renal failure. Many options have been used for the management of uremic pruritus (UP) such as Pregabalin, Gabapentin, Doxepine and Desloratidine. Gabapentin, a GABAergic drug, has been found to be effective in the treatment of uremic pruritus. Doxepin, a potent antihistamine drug, is used orally or topically in many pruritic conditions such as UP, idiopathic pruritus, atopic dermatitis, neurogenic, or psychogenic pruritus and, in the management of the UP in hemodialysis patients.

No comparative head to head study between Gabapentin and Doxepine has been conducted to date. The aim of this study was to compare Gabapentin and Doxepin in treatment of uremic pruritus in hemodialysis patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03758079
Study type	Interventional
Source	University of Balamand
Contact
Status	Completed
Phase	Phase 4
Start date	June 1, 2018
Completion date	October 8, 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04728984` - A Multi-site Bridging Study of Nalfurafine Hydrochloride Orally Disintegrating Tablet	Phase 3
Completed	`NCT02143973` - Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus	Phase 2/Phase 3
Terminated	`NCT01660243` - Efficacy and Safety of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis	Phase 2
Completed	`NCT06159686` - The Efficacy of Hemp-containing Cream Versus Placebo in the Treatment of Uremic Pruritus	Phase 1/Phase 2
Not yet recruiting	`NCT05525234` - A Study of Thalidomide in the Treatment of Refractory Uremic Pruritus	Phase 4
Completed	`NCT03002233` - TRK-820 Study in Subjects on Hemodialysis With or Without Uremic Pruritus	Phase 1
Completed	`NCT03998163` - CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus	Phase 3
Active, not recruiting	`NCT05885737` - Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus	Phase 3
Recruiting	`NCT04393675` - Study to Investigate the Safety of LT5001 Drug Product for Uremic Pruritus in Hemodialysis Patients	Phase 1/Phase 2
Completed	`NCT03576235` - Safety and Efficacy of PG102P for Uremic Pruritus in HD Patients	N/A
Completed	`NCT05575193` - Acupressure on Uremic Pruritus and Sleep Quality Among Patients Receiving Hemodialysis	N/A
Completed	`NCT02858726` - Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus	Phase 2/Phase 3
Completed	`NCT02143648` - Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus	Phase 2/Phase 3
Completed	`NCT00494975` - The Effect of Phototherapy on Pruritus of Patients With Chronic Kidney Disease	N/A
Recruiting	`NCT06446310` - Phase 3 Study of QLG2198 in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus	Phase 3
Completed	`NCT02229929` - Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus	Phase 2
Completed	`NCT04639674` - AST-120 in Hemodialysis Patients With Uremic Pruritus	Phase 4
Completed	`NCT03636269` - CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus	Phase 3
Not yet recruiting	`NCT06466421` - Fexofenadine Versus Gabapentin for Uremic Pruritus in Patients on Regular Hemodialysis	Phase 4
Completed	`NCT04711603` - A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.	Phase 3